Current devices and interventions in mitral regurgitation.
Aktuelle interventionelle Therapieverfahren der Mitralklappeninsuffizienz.
Mitral valve insufficiency
Structural heart disease
Transcatheter mitral valve implantation
Transcatheter mitral valve repair
Transcatheter therapy
Journal
Herz
ISSN: 1615-6692
Titre abrégé: Herz
Pays: Germany
ID NLM: 7801231
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
accepted:
08
07
2021
pubmed:
17
8
2021
medline:
5
10
2021
entrez:
16
8
2021
Statut:
ppublish
Résumé
Mitral regurgitation (MR) is the most common valvular disease. With a rising incidence in older age, the prevalence of relevant comorbidities inevitably increases. Considering the constantly aging population with high surgical risk, transcatheter therapy of MR is gaining increasing importance. Interventional therapy of either primary or secondary MR represents an alternative to pure drug or surgical therapy. With mitral valve transcatheter edge-to-edge repair, a well-established treatment has evolved in the past two decades. In addition, direct or indirect annuloplasty and ultimately transcatheter mitral valve implantation further expand the armamentarium. The current broad spectrum of interventional therapy options allows for patient-oriented therapy individually targeting different MR pathologies. This review discusses the current landscape of transcatheter therapies for relevant MR. Die Mitralklappeninsuffizienz (MI) stellt die häufigste Herzklappenerkrankung dar. Mit einer steigenden Inzidenz im Alter erhöht sich zwangsweise die Prävalenz relevanter Komorbiditäten. In Anbetracht des alternden Patientenkollektivs mit hohem perioperativem Risiko erlangt die interventionelle Versorgung der MI zunehmende Bedeutung. Die interventionelle Therapie der primären sowie sekundären MI stellt somit eine Alternative zur rein medikamentösen bzw. chirurgischen Therapie dar. Während sich in den letzten 2 Dekaden v. a. das Verfahren der Edge-to-Edge-Therapie etablierte, ermöglichen auch andere Therapieoptionen wie eine direkte oder indirekte Annuloplastie sowie nicht zuletzt der interventionelle Mitralklappenersatz eine individuelle Therapieoption. Das aktuell breite Spektrum an interventionellen Verfahren ermöglicht eine patientenorientierte Therapie, die individuell auf die unterschiedlichen Pathologien der MI abzielt. Die vorliegende Übersicht erörtert die aktuellen kathetergestützten Therapien zur Behandlung der relevanten MI.
Autres résumés
Type: Publisher
(ger)
Die Mitralklappeninsuffizienz (MI) stellt die häufigste Herzklappenerkrankung dar. Mit einer steigenden Inzidenz im Alter erhöht sich zwangsweise die Prävalenz relevanter Komorbiditäten. In Anbetracht des alternden Patientenkollektivs mit hohem perioperativem Risiko erlangt die interventionelle Versorgung der MI zunehmende Bedeutung. Die interventionelle Therapie der primären sowie sekundären MI stellt somit eine Alternative zur rein medikamentösen bzw. chirurgischen Therapie dar. Während sich in den letzten 2 Dekaden v. a. das Verfahren der Edge-to-Edge-Therapie etablierte, ermöglichen auch andere Therapieoptionen wie eine direkte oder indirekte Annuloplastie sowie nicht zuletzt der interventionelle Mitralklappenersatz eine individuelle Therapieoption. Das aktuell breite Spektrum an interventionellen Verfahren ermöglicht eine patientenorientierte Therapie, die individuell auf die unterschiedlichen Pathologien der MI abzielt. Die vorliegende Übersicht erörtert die aktuellen kathetergestützten Therapien zur Behandlung der relevanten MI.
Identifiants
pubmed: 34398248
doi: 10.1007/s00059-021-05055-w
pii: 10.1007/s00059-021-05055-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-428Informations de copyright
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Verma S, Latter DA, Bonow RO (2021) Failed mitral TEER are there lessons for decision making? J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2021.04.086
doi: 10.1016/j.jacc.2021.04.086
pubmed: 34556323
pmcid: 8091316
Nkomo VT, Gardin JM, Skelton TN et al (2006) Burden of valvular heart diseases: a population-based study. Lancet 368:1005–1011. https://doi.org/10.1016/s0140-6736(06)69208-8
doi: 10.1016/s0140-6736(06)69208-8
pubmed: 16980116
Dziadzko V, Clavel M‑A, Dziadzko M et al (2018) Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet 391:960–969. https://doi.org/10.1016/s0140-6736(18)30473-2
doi: 10.1016/s0140-6736(18)30473-2
pubmed: 29536860
pmcid: 5907494
Bonow RO, O’Gara PT (2017) Secondary mitral regurgitation and survival in patients with left ventricular dysfunction. JAMA Cardiol 2:1139. https://doi.org/10.1001/jamacardio.2017.3038
doi: 10.1001/jamacardio.2017.3038
pubmed: 28877295
Asgar AW, Mack MJ, Stone GW (2015) Secondary mitral regurgitation in heart failure pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol 65:1231–1248. https://doi.org/10.1016/j.jacc.2015.02.009
doi: 10.1016/j.jacc.2015.02.009
pubmed: 25814231
Punnoose L, Burkhoff D, Cunningham L, Horn EM (2014) Functional mitral regurgitation: therapeutic strategies for a ventricular disease. J Card Fail 20:252–267. https://doi.org/10.1016/j.cardfail.2014.01.010
doi: 10.1016/j.cardfail.2014.01.010
pubmed: 24440574
Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 38:2739–2791. https://doi.org/10.1093/eurheartj/ehx391
doi: 10.1093/eurheartj/ehx391
pubmed: 28886619
Tabata N, Sugiura A, Tsujita K et al (2020) Percutaneous interventions for mitral and tricuspid heart valve diseases. Cardiovasc Interv Ther 35:62–71. https://doi.org/10.1007/s12928-019-00610-z
doi: 10.1007/s12928-019-00610-z
pubmed: 31396890
Otto CM, Nishimura RA, Bonow RO et al (2021) 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation 143:e72–e227. https://doi.org/10.1161/cir.0000000000000923
doi: 10.1161/cir.0000000000000923
pubmed: 33332150
Abraham WT, Fisher WG, Smith AL et al (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845–1853. https://doi.org/10.1056/nejmoa013168
doi: 10.1056/nejmoa013168
pubmed: 12063368
Stone GW, Lindenfeld J, Abraham WT et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379:2307–2318. https://doi.org/10.1056/nejmoa1806640
doi: 10.1056/nejmoa1806640
pubmed: 30280640
Mirabel M, Iung B, Baron G et al (2007) What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 28:1358–1365. https://doi.org/10.1093/eurheartj/ehm001
doi: 10.1093/eurheartj/ehm001
pubmed: 17350971
Baldus S, von Bardeleben RS, Eggebrecht H et al (2020) Interventionelle Therapie von AV-Klappenerkrankungen – Kriterien für die Zertifizierung von Mitralklappenzentren. Kardiologe 14:339–363. https://doi.org/10.1007/s12181-020-00409-w
doi: 10.1007/s12181-020-00409-w
Demir OM, Bolland M, Curio J et al (2021) Transcatheter mitral valve replacement: current evidence and concepts. Interv Cardiol 16:e7. https://doi.org/10.15420/icr.2020.25
doi: 10.15420/icr.2020.25
pubmed: 34035831
pmcid: 8135015
Alfieri O, Maisano F, Bonis MD et al (2001) The double-orifice technique in mitral valve repair: a simple solution for complex problems. J Thorac Cardiovasc Surg 122:674–681. https://doi.org/10.1067/mtc.2001.117277
doi: 10.1067/mtc.2001.117277
pubmed: 11581597
Feldman T, Kar S, Elmariah S et al (2015) Randomized comparison of percutaneous repair and surgery for mitral regurgitation 5‑year results of EVEREST II. J Am Coll Cardiol 66:2844–2854. https://doi.org/10.1016/j.jacc.2015.10.018
doi: 10.1016/j.jacc.2015.10.018
pubmed: 26718672
Feldman T, Foster E, Glower DD et al (2011) Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364:1395–1406. https://doi.org/10.1056/nejmoa1009355
doi: 10.1056/nejmoa1009355
pubmed: 21463154
Lim DS, Reynolds MR, Feldman T et al (2014) Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol 64:182–192. https://doi.org/10.1016/j.jacc.2013.10.021
doi: 10.1016/j.jacc.2013.10.021
pubmed: 24184254
Ailawadi G, Lim DS, Mack MJ et al (2019) One-year outcomes after mitraclip for functional mitral regurgitation. Circulation 139:37–47. https://doi.org/10.1161/circulationaha.117.031733
doi: 10.1161/circulationaha.117.031733
pubmed: 30586701
Szerlip M, Spargias KS, Makkar R et al (2021) 2‑year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. Jacc Cardiovasc Interv. https://doi.org/10.1016/j.jcin.2021.04.001
doi: 10.1016/j.jcin.2021.04.001
pubmed: 34020928
Stone GW, Vahanian AS, Adams DH et al (2015) Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: a consensus document from the mitral valve academic research consortium. J Am Coll Cardiol 66:278–307. https://doi.org/10.1016/j.jacc.2015.05.046
doi: 10.1016/j.jacc.2015.05.046
pubmed: 26184622
Coats AJS, Anker SD, Baumbach A et al (2021) The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the heart failure association (HFA), European association of cardiovascular imaging (EACVI), European heart rhythm association (EHRA), and European association of percutaneous cardiovascular interventions (EAPCI) of the ESC. Eur Heart J 42:1254–1269. https://doi.org/10.1093/eurheartj/ehab086
doi: 10.1093/eurheartj/ehab086
pmcid: 8014526
Adamo M, Godino C, Giannini C et al (2019) Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry. Eur J Heart Fail 21:196–204. https://doi.org/10.1002/ejhf.1343
doi: 10.1002/ejhf.1343
pubmed: 30549159
Geis NA, Puls M, Lubos E et al (2018) Safety and efficacy of MitraClip
doi: 10.1002/ejhf.910
pubmed: 28834079
Neuss M, Schau T, Schoepp M et al (2013) Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regurgitation and severe congestive heart failure. Eur J Heart Fail 15:786–795. https://doi.org/10.1093/eurjhf/hfs214
doi: 10.1093/eurjhf/hfs214
pubmed: 23325017
Swaans MJ, Bakker ALM, Alipour A et al (2014) Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients. Jacc Cardiovasc Interv 7:875–881. https://doi.org/10.1016/j.jcin.2014.01.171
doi: 10.1016/j.jcin.2014.01.171
pubmed: 25147032
Velazquez EJ, Samad Z, Al-Khalidi HR et al (2015) The MitraClip and survival in patients with mitral regurgitation at high risk for surgery: a propensity-matched comparison. Am Heart J 170:1050–1059.e3. https://doi.org/10.1016/j.ahj.2015.08.004
doi: 10.1016/j.ahj.2015.08.004
pubmed: 26542516
Giannini C, Fiorelli F, Carlo MD et al (2016) Comparison of percutaneous mitral valve repair versus conservative treatment in severe functional mitral regurgitation. Am J Cardiol 117:271–277. https://doi.org/10.1016/j.amjcard.2015.10.044
doi: 10.1016/j.amjcard.2015.10.044
pubmed: 26651454
Nickenig G, Estevez-Loureiro R, Franzen O et al (2014) Percutaneous mitral valve edge-to-edge repair in-hospital results and 1‑year follow-up of 628 patients of the 2011–2012 pilot European sentinel registry. J Am Coll Cardiol 64:875–884. https://doi.org/10.1016/j.jacc.2014.06.1166
doi: 10.1016/j.jacc.2014.06.1166
pubmed: 25169171
Keßler M, Seeger J, Muche R et al (2019) Predictors of rehospitalization after percutaneous edge-to-edge mitral valve repair by MitraClip implantation. Eur J Heart Fail 21:182–192. https://doi.org/10.1002/ejhf.1289
doi: 10.1002/ejhf.1289
pubmed: 30178493
Puls M, Lubos E, Boekstegers P et al (2016) One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J 37:703–712. https://doi.org/10.1093/eurheartj/ehv627
doi: 10.1093/eurheartj/ehv627
pubmed: 26614824
Obadia J‑F, Messika-Zeitoun D, Leurent G et al (2018) Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 379:2297–2306. https://doi.org/10.1056/nejmoa1805374
doi: 10.1056/nejmoa1805374
pubmed: 30145927
Iung B, Armoiry X, Vahanian A et al (2019) Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail 21:1619–1627. https://doi.org/10.1002/ejhf.1616
doi: 10.1002/ejhf.1616
pubmed: 31476260
Messika-Zeitoun D, Nickenig G, Latib A et al (2018) Transcatheter mitral valve repair for functional mitral regurgitation using the cardioband system: 1 year outcomes. Eur Heart J 40:466–472. https://doi.org/10.1093/eurheartj/ehy424
doi: 10.1093/eurheartj/ehy424
Miller M, Thourani VH, Whisenant B (2018) The cardioband transcatheter annular reduction system. Ann Cardiothorac Surg 7:741–747. https://doi.org/10.21037/acs.2018.10.10
doi: 10.21037/acs.2018.10.10
pubmed: 30598887
pmcid: 6288207
Patterson T, Adams H, Allen C et al (2019) Indirect annuloplasty to treat functional mitral regurgitation: current results and future perspectives. Front Cardiovasc Med 6:60. https://doi.org/10.3389/fcvm.2019.00060
doi: 10.3389/fcvm.2019.00060
pubmed: 31165074
pmcid: 6536087
Witte KK, Lipiecki J, Siminiak T et al (2019) The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation. JACC Heart Fail 7:945–955. https://doi.org/10.1016/j.jchf.2019.06.011
doi: 10.1016/j.jchf.2019.06.011
pubmed: 31521683
Maniu CV, Patel JB, Reuter DG et al (2004) Acute and chronic reduction of functional mitral regurgitation in experimental heart failure by percutaneous mitral annuloplasty. J Am Coll Cardiol 44:1652–1661. https://doi.org/10.1016/j.jacc.2004.03.085
doi: 10.1016/j.jacc.2004.03.085
pubmed: 15489099
Colli A, Manzan E, Aidietis A et al (2018) An early European experience with transapical off-pump mitral valve repair with NeoChord implantation. Eur J Cardiothorac Surg 54:460–466. https://doi.org/10.1093/ejcts/ezy064
doi: 10.1093/ejcts/ezy064
pubmed: 29514183
Gammie JS, Bartus K, Gackowski A et al (2018) Beating-heart mitral valve repair using a novel ePTFE cordal implantation device: a prospective trial. J Am Coll Cardiol 71:25–36. https://doi.org/10.1016/j.jacc.2017.10.062
doi: 10.1016/j.jacc.2017.10.062
pubmed: 29102688
Sorajja P, Moat N, Badhwar V et al (2019) Initial feasibility study of a new transcatheter mitral prosthesis the first 100 patients. J Am Coll Cardiol 73:1250–1260. https://doi.org/10.1016/j.jacc.2018.12.066
doi: 10.1016/j.jacc.2018.12.066
pubmed: 30898200
Blanke P, Naoum C, Dvir D et al (2017) Predicting LVOT obstruction in transcatheter mitral valve implantation concept of the Neo-LVOT. JACC Cardiovasc Imaging 10:482–485. https://doi.org/10.1016/j.jcmg.2016.01.005
doi: 10.1016/j.jcmg.2016.01.005
pubmed: 26971004
Feldman T, Kar S, Rinaldi M et al (2009) Percutaneous mitral repair with the MitraClip system safety and midterm durability in the initial EVEREST (endovascular valve edge-to-edge REpair study) cohort. J Am Coll Cardiol 54:686–694. https://doi.org/10.1016/j.jacc.2009.03.077
doi: 10.1016/j.jacc.2009.03.077
pubmed: 19679246
Lim DS, Kar S, Spargias K et al (2019) Transcatheter valve repair for patients with mitral regurgitation 30-day results of the CLASP study. Jacc Cardiovasc Interv 12:1369–1378. https://doi.org/10.1016/j.jcin.2019.04.034
doi: 10.1016/j.jcin.2019.04.034
pubmed: 31255562
Nickenig G, Hammerstingl C, Schueler R et al (2016) Transcatheter mitral annuloplasty in chronic functional mitral regurgitation 6‑month results with the cardioband percutaneous mitral repair system. JACC Cardiovasc Interv 9:2039–2047. https://doi.org/10.1016/j.jcin.2016.07.005
doi: 10.1016/j.jcin.2016.07.005
pubmed: 27712741
Nickenig G, Schueler R, Dager A et al (2016) Treatment of chronic functional mitral valve regurgitation with a percutaneous annuloplasty system. J Am Coll Cardiol 67:2927–2936. https://doi.org/10.1016/j.jacc.2016.03.591
doi: 10.1016/j.jacc.2016.03.591
pubmed: 27339489
Beller JP, Rogers JH, Thourani VH, Ailawadi G (2018) Early clinical results with the tendyne transcatheter mitral valve replacement system. Ann Cardiothorac Surg 7:776–779. https://doi.org/10.21037/acs.2018.10.01
doi: 10.21037/acs.2018.10.01
pubmed: 30598892
pmcid: 6288215
Cheung A (2018) Early experience of TIARA transcatheter mitral valve replacement system. Ann Cardiothorac Surg 7:787–791. https://doi.org/10.21037/acs.2018.09.05
doi: 10.21037/acs.2018.09.05
pubmed: 30598894
pmcid: 6288213
Ferreira-Neto AN, Dagenais F, Bernier M et al (2018) Transcatheter mitral valve replacement with a new supra-annular valve first-in-human experience with the altavalve system. JACC Cardiovasc Interv 12:208–209. https://doi.org/10.1016/j.jcin.2018.10.056
doi: 10.1016/j.jcin.2018.10.056